Last reviewed · How we verify
Levocetirizine only
Levocetirizine is a selective H1-receptor antagonist that blocks histamine signaling to reduce allergic symptoms.
Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses. Used for Allergic rhinitis, Chronic urticaria, Allergic conjunctivitis.
At a glance
| Generic name | Levocetirizine only |
|---|---|
| Sponsor | University Hospital, Grenoble |
| Drug class | H1-receptor antagonist (second-generation antihistamine) |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine that selectively antagonizes peripheral H1 receptors. By blocking histamine binding to H1 receptors on mast cells, basophils, and endothelial cells, it prevents the release and effects of histamine, thereby reducing itching, urticaria, rhinitis, and other allergic manifestations. It has minimal central nervous system penetration due to its hydrophilic nature and low blood-brain barrier crossing.
Approved indications
- Allergic rhinitis (seasonal and perennial)
- Chronic urticaria
- Allergic conjunctivitis
Common side effects
- Somnolence
- Headache
- Fatigue
- Dry mouth
- Pharyngitis
Key clinical trials
- Steroid Use in Treatment of Allergic Reactions to Food (PHASE4)
- Traditional vs. Posterior Nasal Radiofrequency Ablation for Chronic Rhinitis (NA)
- A Phase I Study of LY3471851 in Healthy Participants (PHASE1)
- Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis (NA)
- Tranexamic Acid and Spontaneous Chronic Urticaria (PHASE4)
- Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT) (PHASE1)
- Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin. (NA)
- Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levocetirizine only CI brief — competitive landscape report
- Levocetirizine only updates RSS · CI watch RSS
- University Hospital, Grenoble portfolio CI